APEIRON Biologics and MaxCyte Enter into Clinical and Commercial Licensing Agreement for APN401
APEIRON to utilize MaxCyte’s ExPERT® platform for siRNA-based cell therapy APN401 targeting solid tumors and secures manufacturing for upcoming clinical trials. 8 July 2020: Press release (EN) | Presseaussendung (DE)
July 8, 2020
No Comments
APEIRON Biologics closes oversubscribed financing round of EUR 17.5 million for the development of APN01 against COVID-19. Expansion of the ongoing phase II clinical trial to USA and Russia planned.
APEIRON Biologics AG has successfully completed a financing round totaling EUR 17.5 million, thus securing the further development of its drug candidate APN01 for the treatment of seriously ill COVID-19 patients and the further development of immuno-oncology projects. Expansion of the ongoing phase II clinical trial to USA and Russia planned. 3 June 2020: Press...
June 3, 2020
No Comments
APEIRON Biologics announces financing round for the further development of the COVID-19 drug APN01
Substantial financing measures through capital increase with subscription rights and private placement as well as grants Vienna Insurance Group is secured as lead investor of the financing round and secures the private placement Participation in capital increase by existing shareholders as well as new institutional and private investors confirmed Public grant funding committed Financing secures...
May 18, 2020
No Comments
Our work on a potential drug candidate for COVID-19
The Coronavirus disease (COVID-19) is a terrible global pandemic. With our drug candidate APN01, APEIRON Biologics is proud to be among the leading Biotech firms globally, to work on the development of a therapeutic to fight SARS-Cov-2. The story of APN01 APN01 was developed after the first SARS outbreak in the early 2000s. Recently,...
April 2, 2020
No Comments
APEIRON’s respiratory drug product to start pilot clinical trial to treat coronavirus disease COVID-19 in China.
Investigator Initiated Trial (IIT) to start in China, with an international team of experts from China, Austria, and Canada. 24 patients with severe COVID-19 to be treated in a randomized, dual-arm trial with Apeiron’s ACE2 drug product APN01 APN01 was previously proven to be safe and well tolerated in Phase I and Phase II clinical...
February 26, 2020
No Comments
APEIRON Announces Collaboration with Lead Discovery Center GmbH
Alliance for medicinal chemistry optimization and development of novel checkpoint blockade approach. Press release Presseaussendung
September 20, 2018
No Comments
APEIRON Appoints Peter Llewellyn-Davies as Chief Executive Officer
The former CEO Dr. Hans Loibner will continue to support the Company as senior advisor. Press release Presseaussendung
July 17, 2018
No Comments
APEIRON, the Medical University of Vienna and the Institute of Molecular Biotechnology Sign Licensing Agreement for a New Checkpoint Inhibitor.
APEIRON strengthens its proprietary Cbl-b portfolio with cutting edge immunotherapy technology developed at IMBA. Presseaussendung Press Release
July 2, 2018
No Comments